Journal
CLINICS IN LABORATORY MEDICINE
Volume 39, Issue 1, Pages 1-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cll.2018.11.001
Keywords
T-regulatory cells; FOXP3; Immunotherapy
Categories
Funding
- NIDDK NIH HHS [T32 DK007527] Funding Source: Medline
Ask authors/readers for more resources
There has been a prolific amount of research dedicated to the T-regulatory cells (Tregs) and their role in achieving immune homeostasis. Here, the authors briefly discuss the known biology, utilization, and potential of Tregs, for current trials and future immunotherapy. Most current trials of Treg therapies include either ex vivo expanded Tregs transferred into the peripheral blood of patients with diseases of immunologic origin or interleukin 2 injected to stimulate Tregs directly. Ongoing trials designed to measure the clinical efficacy and safety profile of these novel therapeutic approaches have resulted in largely favorable outcomes in a variety of autoimmune and alloimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available